Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Clinical study

Calcitonin gene-related peptide-targeting drugs: Raynaud's syndrome

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Treatment with calcitonin gene-related peptide (CGRP)-targeting drugs may increase the risk of Raynaud's syndrome, according to findings of a study published in the Journal of Headache and Pain. …
Literatur
Zurück zum Zitat Gerard AO, et al. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database Journal of Headache and Pain : 10 May 2022. Available from: URL: http://doi.org/10.1186/s10194-022-01424-w Gerard AO, et al. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database Journal of Headache and Pain : 10 May 2022. Available from: URL: http://​doi.​org/​10.​1186/​s10194-022-01424-w
Metadaten
Titel
Calcitonin gene-related peptide-targeting drugs: Raynaud's syndrome
Publikationsdatum
01.05.2022
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-14897-2

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Elasomeran

Case report

Multiple drugs

Case report

Dupilumab